Researchers from the US National Institutes of Health (NIH) and Marengo Therapeutics Inc. previously developed a first-in-class, bifunctional therapeutic molecule (STAR-0602) that selectively activates V β6 and V β10 T-cell receptor-expressing T cells and boosts antitumor responses in human ex vivo tumor models.

Hutchmed (China) Ltd. has developed HMPL-A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.

CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors.

Two attractive drug targets in tumors are carbonic anhydrase IX (CAIX), which helps maintain pH homeostasis in the hypoxic tumor, and glutathione peroxidase 4 (GPX4), which can reduce oxidative stress. Researchers from Università degli Studi di Firenze and collaborators aimed to inhibit both CAIX and GPX4 simultaneously.

Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its tissue factor-targeting ADC, STRO-004.

South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.